Slater Carla Maria Sena Andrade, Ribeiro Luiz Claudio Pereira, Puccioni-Sohler Marzia
Neuroinfection Clinic, Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro RJ, Brazil.
Arq Neuropsiquiatr. 2012 Sep;70(9):686-90. doi: 10.1590/s0004-282x2012000900007.
The World Health Organization recommends the use of Osame's criterion (1990) for the diagnosis of HTLV-I-associated myelopathy (HAM/TSP). In 2006, a group of neurologists developed a Brazilian criterion that can diagnose HAM/TSP from its onset.
It was to test the agreement between both criteria.
The study included evaluation of clinical and laboratory findings of 35 patients. The ELISA, Western blot and/or polymerase chain reaction was used to search for anti-HTLV-I antibodies. The analysis of agreement was based on the calculation of Kappa.
Concordance of 100% (Kappa=1) occurred in cases of "defined" HAM/TSP, but not in patients with "probable" diagnosis.
The Brazilian criteria was as effective as Osame's criteria for the diagnosis of "defined" HAM/TSP. However, both require more specific biological markers in cerebrospinal fluid for the laboratory diagnosis of probable cases.
世界卫生组织推荐使用大见（Osame）标准（1990年）来诊断人类嗜T淋巴细胞病毒I型相关脊髓病（HAM/TSP）。2006年，一组神经科医生制定了一项巴西标准，该标准能够从疾病发作时诊断HAM/TSP。
检验这两种标准之间的一致性。
该研究纳入了对35例患者的临床和实验室检查结果的评估。采用酶联免疫吸附测定（ELISA）、蛋白质印迹法和/或聚合酶链反应来检测抗人类嗜T淋巴细胞病毒I型抗体。一致性分析基于卡帕（Kappa）值的计算。
在“明确的”HAM/TSP病例中一致性为100%（Kappa = 1），但在“可能的”诊断患者中并非如此。
巴西标准在诊断“明确的”HAM/TSP方面与大见标准同样有效。然而，对于可能病例的实验室诊断，两者都需要脑脊液中更具特异性的生物标志物。
